These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28044961)

  • 1. [An alternative and innovative Research and Development model to ensure access to medicines - Neglected diseases, neglected populations, and biomedical innovation system].
    Pécoul B
    Med Sci (Paris); 2016 Dec; 32(12):1049-1050. PubMed ID: 28044961
    [No Abstract]   [Full Text] [Related]  

  • 2. WHO plans for neglected diseases are wrong.
    Moran M
    Nature; 2014 Feb; 506(7488):267. PubMed ID: 24553204
    [No Abstract]   [Full Text] [Related]  

  • 3. [Description of the French players from Avenir's investment program: the role of MabDesign].
    Groux N; Pontremoli R; Vuddamalay G; Richard G; Pons D
    Med Sci (Paris); 2019 Dec; 35(12):1198-1201. PubMed ID: 31903939
    [No Abstract]   [Full Text] [Related]  

  • 4. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
    Burci GL; Gostin LO
    JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
    [No Abstract]   [Full Text] [Related]  

  • 5. Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system?
    Moon S; Bermudez J; 't Hoen E
    PLoS Med; 2012; 9(5):e1001218. PubMed ID: 22615544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 7. Ask the experts.
    Pecoul B; Pollastri M; McKerrow J; Bueno-Calderon JM
    Future Med Chem; 2012 Jul; 4(11):1383-9. PubMed ID: 22857528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for innovation in global health: a pharmaceutical industry perspective.
    Witty A
    Health Aff (Millwood); 2011 Jan; 30(1):118-26. PubMed ID: 21209447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epilogue: New drugs for neglected diseases.
    Pogge T; Hollis A
    Camb Q Healthc Ethics; 2011 Apr; 20(2):329-34. PubMed ID: 21435308
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical research and pharmacy industry].
    Grandi C
    Rev Fac Cien Med Univ Nac Cordoba; 2013; 70(4):185-6. PubMed ID: 24650648
    [No Abstract]   [Full Text] [Related]  

  • 11. Tropical disease: A neglected cause.
    Laursen L
    Nature; 2016 May; 533(7602):S68-9. PubMed ID: 27167396
    [No Abstract]   [Full Text] [Related]  

  • 12. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What is the fair price of innovative therapy?].
    Fischer A; Dewatripont M; Goldman M
    Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.
    Musselwhite LW; Maciag K; Lankowski A; Gretes MC; Wellems TE; Tavera G; Goulding RE; Guillen E
    Am J Trop Med Hyg; 2012 Jan; 86(1):65-74. PubMed ID: 22232453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Straight talk with...BT Slingsby. Interviewed by Cassandra Willyard.
    Slingsby BT
    Nat Med; 2013 Dec; 19(12):1553. PubMed ID: 24309642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safeguarding innovation through an economic downturn.
    Barker R
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):347-9. PubMed ID: 20715908
    [No Abstract]   [Full Text] [Related]  

  • 18. Patents or patients? Global access to pharmaceuticals and social justice.
    de Wildt G; Khoon CC
    Med Confl Surviv; 2008; 24 Suppl 1():S52-61. PubMed ID: 18771195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternatives to the drug research and development model.
    Velásquez G
    Salud Colect; 2015 Mar; 11(1):23-34. PubMed ID: 25853828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO: Steering plans for neglected diseases.
    Pécoul B; Balasegaram M
    Nature; 2014 Mar; 507(7493):431. PubMed ID: 24670749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.